Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
Information letter on Clexane® (enoxaparin sodium): update of the information on the strength of the medicinal product, as well as on dosage recommendations and recommendations for use
2017.04.13
Active substance: enoxaparin sodium
The company Sanofi-Aventis Deutschland GmbH is sending out information that the information on the effective strength of the medicinal product, the dosage recommendation for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) as well as the recommendations for use in patients with severe renal impairment has been updated.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN